Regulatory tracker: Merck's Welireg picks up FDA priority review in rare tumor bid
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Be sure to come back regularly for …